Immunicum CEO Jamal El-Mosleh said: "We are pleased with the positive news from the Chinese Patent Office, SIPO, which will further strengthen the protection for our main product.
The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the internalization and
174 patients with moderately to severely active Crohn’s disease were enrolled in FITZROY, a double-blind, placebo-controlled Phase 2 study. Patients recruited were either anti-TNF naïve or anti-TNF failures.
Discovered by BioMarin, BMN 250 is being studied in a multicenter, international clinical trial evaluating safety and tolerability, as well as cognitive function of patients with MPS IIIB
Exquiron is a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions. Located near Basel, Switzerland, Exquiron offers industry leading expertise in assay development for
Fibrocell’s azficel-T has the potential to address the underlying cause of chronic dysphonia by using the patient’s own cells for localized treatment of the scarred vocal cords to
"We have now determined the Phase II dose and monotherapy regimen of L-DOS47 for patients that have limited treatment options in our LDOS002 study," said Mr. Steve Demas,
"This CAR-T cell technology licensing further accelerates IMUN’s growth in the Immuno-Oncology field as we evaluate paths to commercialization both in China and other Emerging Markets," commented Christopher
Medidata’s cutting-edge technology platform will support Bristol-Myers Squibb’s research capabilities in immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, genetically modified diseases and metabolics. The Medidata platform has been
The new Center, located on the SBP campus in La Jolla, will bring together experts from SBP and GSK to investigate factors that influence brain function and potentially
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.